Experiments are ongoing in our laboratory to determine whether CSP I-plus could increase other antitumor domains (e.g. interferon α, interleukin-24, tumor necrosis factor α, etc) homing to hepatocellular carcinoma cells and their biologic activity. Here, IL24 is linked to hepatocellular carcinoma.